Skip to content

Zearalenone promotes hepatic lipid accumulation via EGFR-HSP90 complex stabilization.

Sep 2026 · Food Research International · Vol 245 Pt 2, pp. 120789 · 0 citations · 57 references
Medicine

TL;DR

Collectively, ZEA promotes hepatic lipid accumulation via stabilization of the EGFR-HSP90 complex and activation of the EGFR-SREBP1c axis, suggesting EGFR as a potential therapeutic target.

Abstract

Zearalenone (ZEA), a widespread foodborne mycotoxin, has been implicated in metabolic dysfunction-associated fatty liver disease (MAFLD), although its direct hepatic targets and mechanisms remain unclear. This study aimed to identify the molecular target of ZEA and elucidate its role in hepatic lipid dysregulation. Using drug affinity responsive target stability, network toxicology, molecular docking, cellular thermal shift assay, microscale thermophoresis, and molecular dynamics simulations, epidermal growth factor receptor (EGFR) was identified as a direct binding target of ZEA. In C57BL/6J mice (0.5 mg/kg·body weight, 5-day oral gavage) and HepG2 cells (0-20 μM ZEA), ZEA activated EGFR signaling by enhancing transcription and stabilizing EGFR protein via promotion of the EGFR-HSP90 complex. EGFR activation promoted proteolytic cleavage and nuclear translocation of SREBP1c, leading to upregulation of lipogenic enzymes (SCD1, ACC, FASN) and exacerbated lipid accumulation, especially under high fatty acid conditions. Artemether (Art), an artemisinin derivative reported to disrupt the EGFR-HSP90 complex and improve hepatic lipid metabolism, was therefore selected as a therapeutic intervention. Art significantly attenuated EGFR expression and downstream lipogenesis by disrupting the EGFR-HSP90 complex, thereby alleviating ZEA-induced lipid deposition. The EGFR inhibitor erlotinib reversed both ZEA-induced lipogenesis and the protective effects of Art, confirming the central role of EGFR signaling. Collectively, ZEA promotes hepatic lipid accumulation via stabilization of the EGFR-HSP90 complex and activation of the EGFR-SREBP1c axis, suggesting EGFR as a potential therapeutic target.

View source

Similar papers

Open access Oct 2026

Zearalenone acts as a molecular glue to promote K33-linked ubiquitination and degradation of PPARγ and Its effects on glucose metabolism are mitigated by C3G.

It is demonstrated that ZEA functions as a molecular glue, facilitating K33-linked polyubiquitination and proteasomal degradation of PPARγ, thereby suppressing its transcriptional activity and downstream glycolytic gene expression and highlighting C3G as a potential dietary antagonist that safeguards PPARγ stability an...

Bing-Xin Huangfu, Teng Wang, Ya-Nan Chen et al. · 0 citations
Open access Sep 2026

Hepatic Usp2 orchestrates de novo lipogenesis through G3bp2 stabilization and β-catenin activation

The escalating global burden of metabolic diseases including obesity, type 2 diabetes, and metabolic dysfunction-associated fatty liver disease (MAFLD)-highlights an urgent need to identify new therapeutic targets. Although elevated hepatic de novo lipogenesis (DNL) is a hallmark of metabolic dysfunction, targeting i...

Wei Wang, Hui Wang, Yi-Han Liu et al. · 0 citations
Oct 2026

Atractylenolide III alleviates MASLD by inhibiting lipid synthesis and apoptosis via PTEN.

BACKGROUND Metabolic dysfunction-associated steatotic liver disease (MASLD) has emerged as a major global health issue. This study aims to investigate the ameliorative effects of atractylenolide III (ATL III) on MASLD and its underlying molecular mechanisms, thereby providing theoretical basis and experimental support...

Xin-Ru Shen, Lin Chen, Ying-Yi Lian et al. · 0 citations
Open access Sep 2026

NPAS2 promotes MASLD and hepatocarcinogenesis through SIRT1-mediated PPARγ suppression

Emerging evidence links circadian disruption to metabolic dysfunction-associated steatotic liver disease (MASLD), but the underlying mechanisms remain elusive. NPAS2, a core circadian regulator, has an undefined role in the pathogenesis of MASLD and its progression to hepatocellular carcinoma (HCC). This study aime...

Jiao Mu, Jia-Li Ye, Jia-Hao Zhang et al. · 0 citations
Oct 2026

BTRC aggravates FFA-induced lipid accumulation in MASLD via G3BP1 degradation and subsequent SIRT6 mRNA destabilization.

BACKGROUND Metabolic dysfunction associated steatotic liver disease (MASLD) features hepatic steatosis and lipotoxicity, yet its molecular mechanisms remain incompletely understood. How post-transcriptional regulation and protein turnover shape hepatocyte lipid homeostasis in MASLD requires further elucidation. METHO...

Dong-Mei Zou, Liang Liu, Cheng-Yang Yang et al. · 0 citations
Sep 2026

6PPD-Quinone Promotes Metabolic Dysfunction-Associated Steatotic Liver Disease through Immune-Inflammatory Disruption.

6PPD-quinone (6PPDQ), a transformation product of the tire antioxidant 6PPD, is widely detected in environmental and human matrices, yet its relevance to metabolic liver disease remains unclear. We examined its potential contribution to metabolic dysfunction-associated steatotic liver disease (MASLD) by integrating dis...

Xu-Lei Zuo, Li Ma, Xiao-Yu Hou et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.